FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971625745> ?p ?o ?g. }

• W1971625745 endingPage "2265" @default.
• W1971625745 startingPage "2255" @default.
• W1971625745 abstract "Pseudobulbar affect (PBA) is associated with neurological disorders or injury affecting the brain, and characterized by frequent, uncontrollable episodes of crying and/or laughing that are exaggerated or unrelated to the patient's emotional state. Clinical trials establishing dextromethorphan and quinidine (DM/Q) as PBA treatment were conducted in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). This trial evaluated DM/Q safety in patients with PBA secondary to any neurological condition affecting the brain.To evaluate the safety and tolerability of DM/Q during long-term administration to patients with PBA associated with multiple neurological conditions.Fifty-two-week open-label study of DM/Q 30/30 mg twice daily. Safety measures included adverse events (AEs), laboratory tests, electrocardiograms (ECGs), vital signs, and physical examinations.#NCT00056524.A total of 553 PBA patients with >30 different neurological conditions enrolled; 296 (53.5%) completed. The most frequently reported treatment-related AEs (TRAEs) were nausea (11.8%), dizziness (10.5%), headache (9.9%), somnolence (7.2%), fatigue (7.1%), diarrhea (6.5%), and dry mouth (5.1%). TRAEs were mostly mild/moderate, generally transient, and consistent with previous controlled trials. Serious AEs (SAEs) were reported in 126 patients (22.8%), including 47 deaths, mostly due to ALS progression and respiratory failure. No SAEs were deemed related to DM/Q treatment by investigators. ECG results suggested no clinically meaningful effect of DM/Q on myocardial repolarization. Differences in AEs across neurological disease groups appeared consistent with the known morbidity of the primary neurological conditions. Study interpretation is limited by the small size of some disease groups, the lack of a specific efficacy measure and the use of a DM/Q dose higher than the eventually approved dose.DM/Q was generally well tolerated over this 52 week trial in patients with PBA associated with a wide range of neurological conditions." @default.
• W1971625745 created "2016-06-24" @default.
• W1971625745 creator A5009120301 @default.
• W1971625745 creator A5015630437 @default.
• W1971625745 creator A5057886606 @default.
• W1971625745 creator A5058244935 @default.
• W1971625745 creator A5080276406 @default.
• W1971625745 creator A5084490260 @default.
• W1971625745 date "2014-07-28" @default.
• W1971625745 modified "2023-10-16" @default.
• W1971625745 title "An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions" @default.
• W1971625745 cites W1841210729 @default.
• W1971625745 cites W1965432721 @default.
• W1971625745 cites W1965693851 @default.
• W1971625745 cites W1976849943 @default.
• W1971625745 cites W1993289271 @default.
• W1971625745 cites W1996649698 @default.
• W1971625745 cites W2000782600 @default.
• W1971625745 cites W2018930912 @default.
• W1971625745 cites W2021166705 @default.
• W1971625745 cites W2033454748 @default.
• W1971625745 cites W2033528195 @default.
• W1971625745 cites W2042677358 @default.
• W1971625745 cites W2043221233 @default.
• W1971625745 cites W2049032315 @default.
• W1971625745 cites W2055544896 @default.
• W1971625745 cites W2056969868 @default.
• W1971625745 cites W2061197365 @default.
• W1971625745 cites W2063237253 @default.
• W1971625745 cites W2064711426 @default.
• W1971625745 cites W2067764900 @default.
• W1971625745 cites W2077590646 @default.
• W1971625745 cites W2078270682 @default.
• W1971625745 cites W2081713099 @default.
• W1971625745 cites W2084551554 @default.
• W1971625745 cites W2093700893 @default.
• W1971625745 cites W2108568993 @default.
• W1971625745 cites W2120130609 @default.
• W1971625745 cites W2123608858 @default.
• W1971625745 cites W2151178690 @default.
• W1971625745 cites W2151485077 @default.
• W1971625745 cites W2157123931 @default.
• W1971625745 cites W2158974407 @default.
• W1971625745 cites W2167105734 @default.
• W1971625745 cites W2314689571 @default.
• W1971625745 cites W4240492906 @default.
• W1971625745 doi "https://doi.org/10.1185/03007995.2014.940040" @default.
• W1971625745 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4743597" @default.
• W1971625745 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25062507" @default.
• W1971625745 hasPublicationYear "2014" @default.
• W1971625745 type Work @default.
• W1971625745 sameAs 1971625745 @default.
• W1971625745 citedByCount "32" @default.
• W1971625745 countsByYear W19716257452014 @default.
• W1971625745 countsByYear W19716257452015 @default.
• W1971625745 countsByYear W19716257452016 @default.
• W1971625745 countsByYear W19716257452017 @default.
• W1971625745 countsByYear W19716257452018 @default.
• W1971625745 countsByYear W19716257452019 @default.
• W1971625745 countsByYear W19716257452020 @default.
• W1971625745 countsByYear W19716257452021 @default.
• W1971625745 countsByYear W19716257452022 @default.
• W1971625745 countsByYear W19716257452023 @default.
• W1971625745 crossrefType "journal-article" @default.
• W1971625745 hasAuthorship W1971625745A5009120301 @default.
• W1971625745 hasAuthorship W1971625745A5015630437 @default.
• W1971625745 hasAuthorship W1971625745A5057886606 @default.
• W1971625745 hasAuthorship W1971625745A5058244935 @default.
• W1971625745 hasAuthorship W1971625745A5080276406 @default.
• W1971625745 hasAuthorship W1971625745A5084490260 @default.
• W1971625745 hasBestOaLocation W19716257451 @default.
• W1971625745 hasConcept C126322002 @default.
• W1971625745 hasConcept C141071460 @default.
• W1971625745 hasConcept C187212893 @default.
• W1971625745 hasConcept C197934379 @default.
• W1971625745 hasConcept C2778375690 @default.
• W1971625745 hasConcept C2779034229 @default.
• W1971625745 hasConcept C2780168130 @default.
• W1971625745 hasConcept C2780580376 @default.
• W1971625745 hasConcept C71924100 @default.
• W1971625745 hasConceptScore W1971625745C126322002 @default.
• W1971625745 hasConceptScore W1971625745C141071460 @default.
• W1971625745 hasConceptScore W1971625745C187212893 @default.
• W1971625745 hasConceptScore W1971625745C197934379 @default.
• W1971625745 hasConceptScore W1971625745C2778375690 @default.
• W1971625745 hasConceptScore W1971625745C2779034229 @default.
• W1971625745 hasConceptScore W1971625745C2780168130 @default.
• W1971625745 hasConceptScore W1971625745C2780580376 @default.
• W1971625745 hasConceptScore W1971625745C71924100 @default.
• W1971625745 hasIssue "11" @default.
• W1971625745 hasLocation W19716257451 @default.
• W1971625745 hasLocation W19716257452 @default.
• W1971625745 hasLocation W19716257453 @default.
• W1971625745 hasLocation W19716257454 @default.
• W1971625745 hasLocation W19716257455 @default.
• W1971625745 hasLocation W19716257456 @default.
• W1971625745 hasOpenAccess W1971625745 @default.
• W1971625745 hasPrimaryLocation W19716257451 @default.

• next